Status and phase
Conditions
Treatments
About
The purpose of this study is to evaluate the safety and effectiveness of CAR-T cell immunotherapy in patients with CD19 positive relapsed or refractory Leukemia and Lymphoma.
Enrollment
Sex
Ages
Volunteers
Inclusion criteria
Male and female subjects with CD19+ B cell malignancies in patients with no available curative treatment options (such as autologous or allogeneic SCT) who have limited prognosis (several months to < 2 year survival) with currently available therapies will be enrolled:
Exclusion criteria
Primary purpose
Allocation
Interventional model
Masking
10 participants in 1 patient group
Loading...
Central trial contact
Lin Yang, Ph.D.
Data sourced from clinicaltrials.gov
Clinical trials
Research sites
Resources
Legal